The Dawn of Targeted Therapy: How 2025 FDA Approvals are Transforming the IgG4-RD Landscape
Immunoglobulin G4-related disease (IgG4-RD) has long been a challenge for clinicians due to its ability to mimic various malignancies and infections. Characterized by fibro-inflammatory lesions and the infiltration of IgG4-positive plasma cells, this systemic condition can damage the pancreas, kidneys, and salivary glands if left unmanaged. Historically, the medical community relied almost...